Türkiye Initiates Volunteer Screenings for International “Smart Drug” Lymphoma Study

Ankara, The Gulf Observer: Türkiye has emerged as one of the pioneering countries to begin volunteer screenings for a new international “smart drug” study targeting a specific subtype of lymphoma, a cancer originating in the cells of the lymphatic system.

The Phase-1 Clinical Research Center at Ankara University’s Faculty of Medicine, operational for nearly seven months, has been selected to conduct this significant study. Dr. Hakan Ergun, head of the research center, announced the swift initiation of the center’s first international clinical study.

“Our first study at our center has been initiated for a ‘smart drug’ application for lymphoma patients who do not respond to treatment. This covers a special subtype of lymphoma,” stated Dr. Ergun. The drug is administered to patients who have undergone at least two different treatments without success.

Dr. Ergun elaborated on the clinical trials, emphasizing that they are focused on patients likely to benefit from this novel treatment. The international study began simultaneously in three centers across Türkiye, marking a world-first initiative.

“We are currently one of the three centers in Türkiye that have initiated clinical studies on this treatment. We are also proud to be the first in the world, and centers from different countries will also participate in this clinical study later,” Dr. Ergun added.

Highlighting the potential longevity of clinical studies, Dr. Ergun expressed optimism about the benefits for patients involved in the trials. “Our patients participating in the clinical study gain a great advantage regarding the supply of the drug during the period they respond to the treatment,” he noted.

Dr. Ergun conveyed his pride and honor in conducting studies that have the potential to significantly benefit patients suffering from lymphoma.